ClinicalTrials.gg
CompletedNCT01810393Updated Sep 4, 2020

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

A Phase 3 interventional study of Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 61 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
111th of 366
114 · median 61
Started
2013
with 25 others
Phase 3
60 of 374
3 open now
Registered
191st of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 111th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 191st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This open-label, randomized, multicenter study will evaluate participant preference for subcutaneous (SC) versus intravenous (IV) trastuzumab (Herceptin) in participants with HER2-positive metastatic breast cancer responding to first-line treatment with IV trastuzumab for at least 3 years. Participants will be randomized to receive either 3 cycles (cycle length = 21 days) of trastuzumab SC followed by 3 cycles of trastuzumab IV or 3 cycles of trastuzumab IV followed by 3 cycles of trastuzumab SC. All participants will receive trastuzumab SC for Cycles 7 to 18. Anticipated time on study treatment is 1 year or until disease progression or inacceptable toxicity occurs, whichever comes first.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed -positive breast cancer
  • On treatment with trastuzumab IV and free of disease progression for at least 3 years
  • (LVEF) of greater than or equal to (>/=) 50 percent (%)
  • Hormonal therapy will be allowed
  • Prior use of anti-HER2 therapy will be allowed

Exclusion criteria

Exclusion Criteria:

  • History of other , except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years; participants with previous ductal carcinoma in situ of the breast are also eligible
  • Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
  • Serious cardiac illness or medical conditions that would preclude the use of trastuzumab
  • , or infection
  • Pregnant or lactating women
  • Concurrent enrollment in an other clinical trial using an anti-cancer treatment, including hormonal therapy, biphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
  • Known to trastuzumab, murine proteins, to any of the of Herceptin including hyaluronidase or the adhesive of the subcutaneous device, or a history of severe allergic or immunological reactions, for example, difficult to control asthma
  • Central nervous system , unless they have been treated and have been stable for at least 3 years
  • Inadequate organ function
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Trastuzumab IV Then Trastuzumab SC

    Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.

    Drug: Trastuzumab

  • Experimental
    Trastuzumab SC Then Trastuzumab IV

    Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.

    Drug: Trastuzumab

Interventions

  • Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Preference for Either SC or IV Route of Administration According to Participant Preference Questionnaire (PPQ) Score

    Time frame: Baseline up to 6 cycles (cycle length = 21 days)

Secondary outcomes

  1. Percentage of Participants With Adverse Events

    Time frame: approximately 4 years

  2. Percentage of Health Care Professionals With Preference for Either SC or IV Administration According to Health Care Professional Questionnaire (HCPQ) Score

    Time frame: Baseline up to 6 cycles (cycle length = 21 days)

07

Study locations

61 sites
  • Clinique Du Docteur Calabet; Cromg
    Agen, 47000, France
  • Clinique De L Europe; Radiotherapie Chimiotherapie
    Amiens, 80090, France
  • ICO Paul Papin; Oncologie Medicale.
    Angers, 49055, France
  • HOP Prive Arras Les Bonnettes; Chimiotherapie
    Arras, 62012, France
  • Institut Sainte-Catherine; Oncologie
    Avignon, 84082, France
  • Centre Hospitalier de La Cote Basque; Oncologie
    Bayonne, 64109, France
  • HOPITAL JEAN MINJOZ; Oncologie
    Besancon, 25030, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre Hospitalier Fleyriat; Oncologie/Hematologie
    Bourg En Bresse, 01012, France
  • Hopital Morvan
    Brest, 29200, France
  • Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie
    Brest, 29220, France
  • Centre Francois Baclesse; Oncologie
    Caen, 14076, France
  • Centre Jean Perrin; Oncologie
    Clermont Ferrand, 63011, France
  • Pole Sante Republique;Oncologie Hematologie
    Clermont Ferrand, 63050, France
  • Chi De Creteil; Radiotherapie Oncologie
    Creteil, 94010, France
  • Centre Leonard De Vinci;Chimiotherapie
    Dechy, 59187, France
  • Centre Georges Francois Leclerc; Oncologie 3
    Dijon, 21079, France
  • CHD Les Oudairies
    La Roche Sur Yon, 85925, France
  • Ch Louis Pasteur; Oncologie
    Le Coudray, 28630, France
  • Clinique Victor Hugo; Radiotherapie
    Le Mans, 72015, France
  • Polyclinique Du Bois; Oncologie
    Lille, 59003, France
  • Centre Oscar Lambret; Unite de Recherche Clinique
    Lille, 59020, France
  • Ch Bretagne Sud Site Scorff; Oncologie Medicale
    Lorient, 56100, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Clinique De La Sauvegarde; Chimiotherapie
    Lyon, 69337, France
  • Hopital Prive Jean Mermoz
    Lyon, 69373, France
  • Institut Paoli Calmettes; Oncologie Medicale
    Marseille, 13273, France
  • Hopital de Mercy ;ONCOLOGIE MEDICALE
    Melz, 57085, France
  • Hopital Belle Isle; Oncologie Hematologie
    Metz, 57045, France
  • Clinique Clementville; Hopital De Jour
    Montpellier, 34070, France
  • Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE
    Nancy, 54100, France
  • Centre Catherine de Sienne; Chimiotherapie
    Nantes, 44202, France
  • Centre Antoine Lacassagne
    Nice, 06189, France
  • Institut de cancerologie du Gard
    Nimes, 30029, France
  • HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune
    Orleans, 45100, France
  • APHP - Hopital de la Pitie Salpetriere
    Paris, 75013, France
  • Groupe Hospitalier Diaconesses
    Paris, 75020, France
  • Institut Curie; Oncologie Medicale
    Paris, 75231, France
  • Hopital Saint Louis; Oncologie Medicale
    Paris, 75475, France
  • HOPITAL TENON; Cancerologie Medicale
    Paris, 75970, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers cedex, 86021, France
  • CH d'Annecy
    Pringy, 74370, France
  • Chi De Cornouaille; Oncologie Hospitalisation
    Quimper, 29107, France
  • Institut Jean Godinot; Oncologie Medicale
    Reims CEDEX, 51056, France
  • Institut du Cancer Coulancy Reims
    Reims, 51100, France
  • Centre Eugene Marquis; Bureau D Etudes Cliniques
    Rennes, 35042, France
  • Centre Henri Becquerel; Oncologie Medicale
    Rouen, 76038, France
  • Chp Saint Gregoire; Cancerologie Radiotherapie
    Saint Gregoire, 35768, France
  • Centre Rene Gauducheau
    Saint Herblain, 44805, France
  • Polyclinique de la Cote Basque Sud; Oncologie
    Saint Jean de Luz, 64501, France
  • Clinique Mutualiste L Estuaire
    Saint Nazaire, 44606, France
  • CH de Saint Quentin
    Saint Quentin, 2100, France
  • Hopital Prive Nord Parisien; Soins De Suite - Oncologie
    Sarcelles, 95200, France
  • CMCO De La Cote D Opale; Auberge De Jour
    St Martin Boulogne, 62280, France
  • Institut de Cancérologie de Loire
    St-Priest-En-Jarez, 42271, France
  • Clinique Ste Anne
    Strasbourg, 67000, France
  • Centre Paul Strauss; Oncologie Medicale
    Strasbourg, 67065, France
  • Hopital de Hautepierre
    Strasbourg, 67091, France
  • Hôpital Rangueil - CHU de Toulouse
    Toulouse, 31059, France
  • Clinique Pasteur; Oncologie Medicale
    Toulouse, 31076, France
08

References and documents

Publications

  • Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. Eur J Cancer. 2017 Sep;82:230-236. doi: 10.1016/j.ejca.2017.05.009. Epub 2017 Jun 23. PubMed 28648618 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jul 2019, 73 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 73 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2013
First posted
Mar 13, 2013
StartActual
Jun 11, 2013
Primary completionActual
Jul 17, 2019
CompletionActual
Jul 17, 2019
Last update
Sep 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01810393
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 13, 2013
Start date
Jun 11, 2013
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019
Last update
Sep 4, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion